Novacap subsidiary starts work on pharma-grade sodium bicarbonate plant in Singapore

By Gareth Macdonald

- Last updated on GMT

iStock/Geo-grafika
iStock/Geo-grafika

Related tags Singapore

Novacap has started building a sodium bicarbonate production facility in Singapore, citing Asian drug and food manufacturers as target customers.

The facility - which is at a site on Jurong, an artificial island off the southwest of the main island of Singapore – will produce 70,000 metric tons of pharmaceutical-grade sodium bicarbonate a year.

Manufacturing will adhere to principles and technology developed by Novacap’s subsidiary Novacarb at its facility in Nancy, France.

The approach - developed by Novacarb as part of its €15m "Bianca" project - combines manufacturing technologies and worker training.

The Singapore facility will be operated by Novabay Pte Ltd and is scheduled to begin production activities in the second quarter of 2017.

Novabay Pte president, Raymond Sinnah, said: “This will enable us to offer high-quality grades and a strong alternative of Sodium Bicarbonate supply in Asia. Singapore is a perfect location and logistic hub to capture the growth and to efficiently serve our customers and targeted markets." 

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars